Breaking: Tyson Foods Q3 Misses Mark; Ginkgo Bioworks' Merck Deal Shakes Up
- August 07th, 2023
- 391 views
Tyson Foods, Inc. (NYSE: TSN) has released its third-quarter fiscal 2023 financial results, reporting adjusted earnings per share (EPS) of $0.15 and revenues totaling $13.14 billion. These figures fell short of market consensus estimates of $0.26 EPS on revenues of $13.59 billion.
$TSN was trading at $52.67 in pre-market, down $3.79 (-6.71%).
In other news, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has unveiled a strategic partnership with Merck & Co., Inc. (NYSE: MRK).
The collaboration agreement, which marks the second between the companies and is aimed at improving biologic manufacturing, outlines the potential for Ginkgo to receive up to $490 million, encompassing upfront research fees, milestones, and commercial payments.
In pre-market, $DNA was trading at $2.18, reflecting an increase of $0.14 (+6.86%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login